arrow
J

Jonas Willmann

University of Zurich
H指数:14
被引数:981

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

How to plan and deliver lung cancer reirradiation: A consensus approach from the ESTRO reirradiation and lung focus groups and ReCOG

如何规划和实施肺癌再程放疗:ESTRO再程放疗与肺癌重点小组及ReCOG的共识方法

2026-10-210
OA
The impact of national health systems on lung cancer mortality

国家卫生系统对肺癌死亡率的影响

Chest
IF8.6
2026-08-290
PRE
Leveraging the potential of prospective registries for radiation oncology research: 5-year experience from the EORTC-ESTRO radiotherapy infrastructure for Europe (E2-RADIatE) project

利用前瞻性登记研究的潜力进行放射肿瘤学研究:欧洲放射治疗基础设施EORTC-ESTRO项目(E2-RADIatE)5年经验

2026-06-060
PRE
Letter to the Editor regarding Questionable indication for postoperative radiotherapy after surgery for metastases of the major long bones: A cautionary note on methodology and analysis

致编辑函:关于主要长骨转移术后放疗可疑适应症的质疑——对方法和分析的警示性说明

2026-06-010
OAAI
Clinical evidence and reporting standards in reirradiation: Insights from 28 studies at ESTRO 2025, endorsed by the ESTRO reirradiation focus group

再放疗的临床证据与报告标准:来自ESTRO 2025年会上28项研究的见解,并由ESTRO再放疗重点小组认可

2025-12-010
OAAI
Multinational Validation of Distant Metastasis Velocity as a Post-Progression Prognostic Score in Patients with Oligometastatic Cancer Treated with Metastasis-Directed Stereotactic Body Radiotherapy

多国验证远处转移速度作为接受转移灶定向立体定向体部放疗的寡转移癌患者中的一种疾病进展后预后评分

2025-08-230
OAAI
Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedure

胶质母细胞瘤的随机多中心III期临床试验EORTC-1709-BTG/CCTG CE.8 (MIRAGE)中的质量保证:放射治疗勾画基准案例程序的结果

2025-08-100
PRE
Rationale and design of the AUSTRAL trial: An open-label, multicenter, phase II study evaluating radiotherapy followed by durvalumab (MEDI4736) and ceralasertib (AZD6738) in stage III NSCLC patients with thoracic relapses and/or oligometastases after the PACIFIC regimen.

AUSTRAL试验的原理与设计:一项开放标签、多中心、II期研究,旨在评估在完成PACIFIC方案治疗后出现胸腔内复发和/或寡转移的III期NSCLC患者中,采用放疗后序贯度鲁瓦木单抗(MEDI4736)和塞拉拉塞替(AZD6738)的治疗效果。

2025-07-120
PRE
Reirradiation: Standards, challenges, and patient-focused strategies across tumor types

再照射:标准、挑战及跨肿瘤类型的患者中心策略

2025-05-290
OAAI